-
Evaluating Safety and Early Outcomes of Lecanemab Treatment for Alzheimer Disease: Philip Kuball, MD
18 Apr 2025 17:23 GMT
… (Leqembi; Eisai), an FDA-approved treatment for Alzheimer disease (AD), … for Memory Evaluation & Treatment, met regularly to unanimously … diagnosis via CSF or Amyvid PET, Mini-Mental State … the phase 3 Clarity AD trial (NCT03887455). At baseline, …
-
EMA Recommends Five New Medicines for Approval
28 Mar 2025 21:17 GMT
… (acalabrutinib), Flucelvax (influenza vaccine—surface antigen, inactivated, prepared … recommended a new pharmaceutical form as well … an herbal medicine for treatment of moderate-to … Amyvid (florbetapir [18F]) in adults, to monitor their response to treatments …
-
Withdrawn application: Amyvid, 26/02/2025
28 Mar 2025 16:21 GMT
… that Amyvid could not have been authorised to monitor treatment response … well Amyvid PET scans perform when used to monitor treatment response … with the performance of Amyvid PET scans when used … the method for interpreting Amyvid PET scans may require …
-
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 March 2025
28 Mar 2025 16:12 GMT
… -clinical tests and clinical trials of an already-authorised … also recommended a new pharmaceutical form and a new … as a herbal medicine for the treatment of moderate-to-severe … Amyvid (florbetapir (18F)) in adults to monitor their response to treatments …
-
CuraSen Therapeutics Announces First Subject Treated with CuraAX (CST-3056) in a Phase 1 Clinical Trial
20 Feb 2025 14:25 GMT
… the development of new treatments for psychiatric and neurodegenerative … in academia and the biotech industry. The ADDF… #39;s PET scan (Amyvid®) and blood test (PrecivityAD®) … drug discovery and development programs, biomarker programs and clinical trials …
-
ALZHEIMER’S DRUG DISCOVERY FOUNDATION’S DIAGNOSTICS ACCELERATOR (DXA) Invests $1.4M in ViewMind’s technology.
28 Jan 2025 11:30 GMT
… impact of treatment would be very impactful for drug development and … research in academia and the biotech industry. The ADDF… 's PET scan (Amyvid®) and blood test (PrecivityAD®) … ;s drug discovery programs, biomarker programs and clinical trials in …
-
New Investment From The Alzheimer's Drug Discovery Foundation's Diagnostics Accelerator (Dxa) Leads Efforts To Develop Standardization Materials For Leading Diagnostic Biomarker
14 Nov 2024 23:38 GMT
… medicine approach, representing the future of Alzheimer's treatment. … research in academia and the biotech industry. The ADDF… 's PET scan (Amyvid®) and blood test (PrecivityAD®) … ;s drug discovery programs, biomarker programs and clinical trials in …
-
GLX Analytix Announces Strategic Investment from Labcorp Venture Fund and Alzheimer’s Drug Discovery Foundation (ADDF)
29 Oct 2024 14:00 GMT
… services that helps doctors, hospitals, pharmaceutical companies, researchers, … in academia and the biotech industry. The ADDF … drug discovery programs, biomarker programs and clinical trials in … of more targeted treatments.
Maital Rasmussen
Chief …
-
Human medicines European public assessment report (EPAR): Amyvid, florbetapir (18F), Date of authorisation: 14/01/2013, Revision: 15, Status: Authorised
21 Oct 2024 15:13 GMT
The active substance in Amyvid, florbetapir (18F), is a radiopharmaceutical … on the PET scan, enabling doctors to know whether or not … elderly people with no symptoms. Doctors will therefore need to use …
-
Alzheimer’s Drug Discovery Foundation’s Diagnostics Accelerator (DxA) Invests More Than $7 Million in C2N Diagnostics’ Blood Tests
25 Sep 2024 18:36 GMT
… medicine—the holy grail of Alzheimer’s treatment.
ABOUT THE ALZHEIMER’S DRUG … ’s PET scan (Amyvid®) and blood test … includes landmark treatment and prevention trials involving disease- … with multi-national pharmaceutical and biotech companies, leading …
About
© 1995-2025